Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of chlorogenic acid in preparing medicament for treating marrow fibrillation

A technology for bone marrow fibrosis and chlorogenic acid, which can be used in drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., and can solve problems such as chlorogenic acid that have not been discovered

Active Publication Date: 2010-04-21
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, no relevant reports have been found that chlorogenic acid has an impact on bone marrow efficacy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of chlorogenic acid in preparing medicament for treating marrow fibrillation
  • Use of chlorogenic acid in preparing medicament for treating marrow fibrillation
  • Use of chlorogenic acid in preparing medicament for treating marrow fibrillation

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0035] [Experimental Example 1] The effect of chlorogenic acid on bone marrow suppression caused by physical factors in mice

[0036] Chlorogenic acid, with a content of 99.56%, is prepared into the required concentration with sodium chloride injection. Positive control drug: recombinant human granulocyte colony-stimulating factor injection, 300ug / bottle, 1.2ml / bottle.

[0037] SPF grade ICR mice, weighing 22-30 g, 240. According to body weight and sex, they were randomly divided into high-, medium-, and low-dose groups of chlorogenic acid, positive control group, model control group, and normal control group, with 40 rats in each group, half male and half male. Except for the normal control group, other animals were treated with 60 Whole body irradiation with Coγ-rays, the irradiation dose is 4Gy (dose rate 256Gy / h, irradiation time is 2min), after irradiation, each group is given the corresponding test substance according to Table 1 (the control group and the model group a...

experiment example 2

[0094] [Experimental Example 2] The effect of chlorogenic acid on bone marrow suppression caused by chemical factors in dogs

[0095] Chlorogenic acid, content 99.56%, positive control drug: Likejun tablet, 20mg / tablet, three times a day (3 tablets), cyclophosphamide for injection (abbreviated as CY), white powder, 200mg / ampule, 5 tubes / boxed. Beagle dogs, 36 (half male and half female), normal, healthy, uniform weight, non-pregnant female, weighing 6-7kg, aged 6 months.

[0096] See Table 19 for dose design.

[0097] Table 19 Dose Design

[0098]

[0099] Except the normal control group, the other 5 groups of dogs were intravenously injected with 8mg / ml cyclophosphamide 0.8ml / kg (8mg / kg), once a day for 5 consecutive days. On the 6th day, each test drug was administered according to Table 19, and normal saline was administered to the model control group and the normal control group for 13 consecutive days. Before modeling, every day after modeling, and 2, 4, 6, 8, 10,...

experiment example 3

[0127] [Experimental Example 3] Chlorogenic acid pair 60 Protective Effect of Co-γ-ray Injury on Spleen Hematopoietic Stem Cells in Mice

[0128] 1. Experimental method

[0129] Take Health C 57Sixty mice were randomly divided into 5 groups according to sex and body weight. Administration is divided into groups respectively, each mouse of negative group injects normal saline 0.4ml / 20g body weight intraperitoneally, and each mouse of positive group (granulocyte colony-stimulating factor) gives 0.4ml / 20g body weight (2ug / kg) by intraperitoneal injection, and all the other three groups are treated with 0.1%, 0.05% and 0.025% chlorogenic acid medicinal solution was intraperitoneally injected 0.4ml / 20g body weight (dose 20, 10 and 5mg / kg) to each mouse in each group. All rats in the above five groups were administered once a day for 7 consecutive days, and the body weight of the surviving animals was weighed on the 7th day, and 1 hour after the last administration. The mice in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of chlorogenic acid in preparing medicament for treating marrow fibrillation and also provides a pharmaceutical composition containing the chlorogenic acid as the active constituent.

Description

[0001] This application is a divisional application of application number: 200680024175.X (PCT / CN2006 / 001795). Original application number: 200680024175.X (PCT / CN2006 / 001795), application date: July 21, 2006, invention name: the use of chlorogenic acid in the preparation of drugs with the effect of increasing bone marrow cells. technical field [0002] The invention relates to a new application of chlorogenic acid, specifically, the application of chlorogenic acid in the preparation of medicine for treating myelofibrosis. Background technique [0003] Chlorogenic acid is widely found in various medicinal plants such as honeysuckle, and its chemical structure has been clearly studied. Some people have conducted medicinal research on it, and it has been reported that chlorogenic acid can be used to treat diseases such as tumors. [0004] Chlorogenic acid is a phenolic compound isolated from the leaves and fruits of dicotyledonous plants (such as honeysuckle leaves, coffee bean...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P43/00
Inventor 张洁张舒张亮徐小平包旭易大朝
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com